FDA to review Mylan's marketing application for Neulasta biosimilar; shares up a fraction premarket

• The FDA accepts for review Mylan's (MYL) Biologics License Application (BLA) seeking approval of a biosimilar to Amgen's (AMGN) Neulasta (pegfilgrastim). The agency's action (PDUFA) date is October 9.
• Mylan developed the product in collaboration with India-based Biocon Ltd. (OTC:BCNQY).